Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results Meeting Abstract
| Authors: | Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; Moore, K.; Hamilton, E.; Yeku, O.; Bouberhan, S.; Hou, J.; Schröder, D.; Wang, B.; Yoo, S. Y.; Govindraj, S.; Brouwer-Visser, J.; Peterman, M.; Schmidt, T.; Barnes, B.; Lowy, I.; Uldrick, T.; Miller, E.; O'Cearbhaill, R. |
| Abstract Title: | Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results |
| Meeting Title: | IGCS 2023 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Nov 5-7 |
| Meeting Location: | Seoul, South Korea |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2023-11-01 |
| Start Page: | A9 |
| End Page: | A10 |
| Language: | English |
| ACCESSION: | WOS:001262421600045 |
| DOI: | 10.1136/ijgc-2023-IGCS.11 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PO011LBA/#1512 -- Source: Wos |
